HRP20120067T1 - Citotoksična sredstva koja sadrže nove derivate tomamicina i njihova upotreba u terapiji - Google Patents
Citotoksična sredstva koja sadrže nove derivate tomamicina i njihova upotreba u terapiji Download PDFInfo
- Publication number
- HRP20120067T1 HRP20120067T1 HR20120067T HRP20120067T HRP20120067T1 HR P20120067 T1 HRP20120067 T1 HR P20120067T1 HR 20120067 T HR20120067 T HR 20120067T HR P20120067 T HRP20120067 T HR P20120067T HR P20120067 T1 HRP20120067 T1 HR P20120067T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- ethoxy
- yloxymethyl
- methoxy
- bis
- Prior art date
Links
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (E)-tomaymycin Chemical class CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 239000002254 cytotoxic agent Substances 0.000 title 1
- 231100000599 cytotoxic agent Toxicity 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 12
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 150000004677 hydrates Chemical class 0.000 claims abstract 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000013078 crystal Substances 0.000 claims abstract 3
- 150000002148 esters Chemical class 0.000 claims abstract 3
- 230000003287 optical effect Effects 0.000 claims abstract 3
- 239000011230 binding agent Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 claims 2
- 108010074338 Lymphokines Proteins 0.000 claims 2
- 102000008072 Lymphokines Human genes 0.000 claims 2
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 claims 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 claims 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 2
- 235000019260 propionic acid Nutrition 0.000 claims 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims 2
- 230000009257 reactivity Effects 0.000 claims 2
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 claims 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 1
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 1
- 238000005377 adsorption chromatography Methods 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 229940094957 androgens and estrogen Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940047120 colony stimulating factors Drugs 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940014144 folate Drugs 0.000 claims 1
- -1 folate Natural products 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 238000005227 gel permeation chromatography Methods 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000003270 steroid hormone Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290904.7A EP2019104B1 (de) | 2007-07-19 | 2007-07-19 | Zytotoxische Mittel mit neuen Tomaymycin-Derivaten und ihre therapeutische Verwendung |
| PCT/IB2008/002869 WO2009016516A2 (en) | 2007-07-19 | 2008-07-18 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120067T1 true HRP20120067T1 (hr) | 2012-02-29 |
Family
ID=39048765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120067T HRP20120067T1 (hr) | 2007-07-19 | 2012-01-23 | Citotoksična sredstva koja sadrže nove derivate tomamicina i njihova upotreba u terapiji |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US8404678B2 (de) |
| EP (2) | EP2019104B1 (de) |
| JP (1) | JP5551070B2 (de) |
| KR (1) | KR101627871B1 (de) |
| CN (1) | CN101784550B (de) |
| AR (1) | AR067575A1 (de) |
| AT (1) | ATE530553T1 (de) |
| AU (1) | AU2008281439B2 (de) |
| BR (1) | BRPI0814267A2 (de) |
| CA (1) | CA2693551C (de) |
| CL (1) | CL2008002139A1 (de) |
| CO (1) | CO6290692A2 (de) |
| CR (1) | CR11225A (de) |
| CY (2) | CY1112278T1 (de) |
| DK (2) | DK2019104T3 (de) |
| DO (1) | DOP2010000014A (de) |
| EA (1) | EA019938B1 (de) |
| EC (1) | ECSP109875A (de) |
| ES (2) | ES2435779T3 (de) |
| GT (1) | GT201000008A (de) |
| HK (1) | HK1144289A1 (de) |
| HR (1) | HRP20120067T1 (de) |
| IL (1) | IL203318A (de) |
| JO (1) | JO2744B1 (de) |
| MA (1) | MA31617B1 (de) |
| ME (1) | ME00969B (de) |
| MY (1) | MY151245A (de) |
| NI (1) | NI201000005A (de) |
| NZ (1) | NZ582679A (de) |
| PA (1) | PA8790201A1 (de) |
| PE (2) | PE20090889A1 (de) |
| PL (2) | PL2019104T3 (de) |
| PT (2) | PT2019104E (de) |
| RS (1) | RS52245B (de) |
| SI (2) | SI2019104T1 (de) |
| TN (1) | TN2010000002A1 (de) |
| TW (1) | TWI500618B (de) |
| UA (1) | UA98153C2 (de) |
| WO (1) | WO2009016516A2 (de) |
| ZA (1) | ZA201000389B (de) |
Families Citing this family (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1928503T1 (sl) | 2005-08-24 | 2012-11-30 | Immunogen Inc | Postopek za pripravo konjugatov majtansinoid protitelo |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| DE102008056086A1 (de) * | 2008-11-06 | 2010-05-12 | Gp Solar Gmbh | Additiv für alkalische Ätzlösungen, insbesondere für Texturätzlösungen sowie Verfahren zu dessen Herstellung |
| AU2015224492B2 (en) * | 2009-02-05 | 2017-04-20 | Immunogen, Inc. | Novel benzodiazepine derivatives |
| RU2545080C2 (ru) * | 2009-02-05 | 2015-03-27 | Иммьюноджен, Инк. | Новые производные бензодиазепина |
| CN104984360A (zh) | 2009-06-03 | 2015-10-21 | 伊缪诺金公司 | 轭合方法 |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| FR2949469A1 (fr) * | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| US8410127B2 (en) | 2009-10-01 | 2013-04-02 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| CN105001334A (zh) | 2010-02-10 | 2015-10-28 | 伊缪诺金公司 | Cd20抗体及其用途 |
| EP2558475A1 (de) | 2010-04-15 | 2013-02-20 | Spirogen Sàrl | Pyrrolobenzodiazepine zur behandlung proliferativer erkrankungen |
| US9242013B2 (en) | 2010-04-15 | 2016-01-26 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
| PE20130342A1 (es) * | 2010-04-15 | 2013-04-20 | Spirogen Sarl | Pirrolobenzodiacepinas y conjugados de las mismas |
| BR112012032248A2 (pt) | 2010-06-23 | 2016-09-13 | Metabolex Inc | composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina |
| FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
| PL2675479T3 (pl) * | 2011-02-15 | 2016-09-30 | Cytotoksyczne pochodne benzodiazepiny | |
| KR102272828B1 (ko) | 2011-03-29 | 2021-07-05 | 이뮤노젠 아이엔씨 | 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조 |
| WO2012145112A2 (en) * | 2011-04-18 | 2012-10-26 | Immunogen, Inc. | Novel maytansinoid derivatives with sulfoxide linker |
| KR101860174B1 (ko) | 2011-09-20 | 2018-05-21 | 메디뮨 리미티드 | 표적 접합체 내의 내포를 위한 비대칭 이량체 pbd 화합물로서 피롤로벤조디아제핀 |
| CN110183470A (zh) | 2011-10-14 | 2019-08-30 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓 |
| US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| BR112014009055B1 (pt) | 2011-10-14 | 2021-12-14 | Seattle Genetics, Inc. | Compostos pirrolobenzodiazepinas, conjugados alvos, ligante de fármaco e uso dos ditos conjugados para tratar uma doença proliferativa |
| US9399073B2 (en) | 2011-10-14 | 2016-07-26 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines |
| MX2014007125A (es) * | 2011-12-13 | 2015-04-16 | Immunogen Inc | Uso de n-hidroxisuccinimida para mejorar la estabilidad de conjugados. |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| AU2013256596A1 (en) | 2012-05-01 | 2014-10-09 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| JP2015523380A (ja) | 2012-07-09 | 2015-08-13 | ジェネンテック， インコーポレイテッド | 抗ｃｄ７９ｂ抗体を含む免疫複合体 |
| SG11201500087VA (en) | 2012-07-09 | 2015-02-27 | Genentech Inc | Immunoconjugates comprising anti-cd22 antibodies |
| BR112015002193A2 (pt) | 2012-08-02 | 2017-07-04 | Genentech Inc | anticorpos anti-etbr e imunoconjugados |
| EP2887965A1 (de) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Zytotoxische benzodiazepin-derivate |
| AU2013326881B2 (en) * | 2012-10-04 | 2018-08-02 | Immunogen, Inc. | Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates |
| EP2906250B1 (de) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate |
| WO2014057072A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| KR101819404B1 (ko) | 2012-10-12 | 2018-02-28 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
| CA2885315C (en) | 2012-10-12 | 2020-06-23 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| PL2906253T3 (pl) | 2012-10-12 | 2019-02-28 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina-przeciwciało anty-psma |
| MX364329B (es) | 2012-10-12 | 2019-04-23 | Medimmune Ltd | Conjugados del anticuerpo pirrolobenzodiazepina. |
| AU2013328628B2 (en) | 2012-10-12 | 2016-12-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
| ES2660029T3 (es) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Conjugados de anticuerpo-pirrolobenzodiazepinas |
| CN105102068B (zh) | 2012-10-12 | 2018-06-01 | Adc疗法责任有限公司 | 吡咯并苯并二氮杂卓-抗体结合物 |
| WO2014080251A1 (en) | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| KR102066318B1 (ko) * | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
| BR112015023070B1 (pt) * | 2013-03-13 | 2022-06-07 | Genentech, Inc. | Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa |
| CA2901312C (en) | 2013-03-13 | 2022-09-06 | Seattle Genetics, Inc. | Activated carbon filtration for purification of benzodiazepine adcs |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| JP6436965B2 (ja) | 2013-03-14 | 2018-12-12 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及びイムノコンジュゲート |
| BR112016002829A2 (pt) | 2013-08-12 | 2017-09-19 | Genentech Inc | Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi |
| CN105518027A (zh) | 2013-09-17 | 2016-04-20 | 豪夫迈·罗氏有限公司 | 使用抗lgr5抗体的方法 |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| PE20160712A1 (es) | 2013-12-13 | 2016-07-26 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd33 |
| KR20160092024A (ko) | 2013-12-16 | 2016-08-03 | 제넨테크, 인크. | 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법 |
| ES2960619T3 (es) | 2014-02-28 | 2024-03-05 | Hangzhou Dac Biotech Co Ltd | Enlazadores cargados y sus usos para la conjugación |
| CN106414499A (zh) | 2014-05-22 | 2017-02-15 | 基因泰克公司 | 抗gpc3抗体和免疫偶联物 |
| CA2959141A1 (en) | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| TWI757759B (zh) | 2014-09-03 | 2022-03-11 | 美商免疫原公司 | 細胞毒性苯并二氮呯衍生物 |
| EP3189057A1 (de) | 2014-09-03 | 2017-07-12 | ImmunoGen, Inc. | Zytotoxische benzodiazepin-derivate |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP3191518B1 (de) | 2014-09-12 | 2020-01-15 | Genentech, Inc. | Anti-b7-h4-antikörper und immunkonjugate |
| KR20170052600A (ko) | 2014-09-12 | 2017-05-12 | 제넨테크, 인크. | 시스테인 가공된 항체 및 콘주게이트 |
| PT3191135T (pt) | 2014-09-12 | 2020-11-12 | Genentech Inc | Anticorpos anti-her2 e imunoconjugados |
| AR101846A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos anti-cll-1 e inmunoconjugados |
| JP6730261B2 (ja) | 2014-09-17 | 2020-07-29 | ジェネンテック， インコーポレイテッド | 抗ｈｅｒ２抗体を含む免疫複合体 |
| CN107148285B (zh) * | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| CA2973354A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
| CN107231804B (zh) | 2015-01-14 | 2019-11-26 | 百时美施贵宝公司 | 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法 |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| EP3313854A1 (de) | 2015-06-23 | 2018-05-02 | Bristol-Myers Squibb Company | Makrocyclische benzodiazepindimere, konjugate davon, herstellung und verwendung |
| CA2991973C (en) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Bridge linkers for conjugation of a cell-binding molecule |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| KR20180038460A (ko) | 2015-07-21 | 2018-04-16 | 이뮤노젠 아이엔씨 | 세포독성 벤조다이아제핀 유도체의 제조 방법 |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| WO2017107817A1 (zh) * | 2015-12-21 | 2017-06-29 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| KR20200087875A (ko) | 2016-04-15 | 2020-07-21 | 바이오아트라, 엘엘씨 | 항 Axl항체 및 이의 면역접합체와 이것들의 용도 |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| WO2017196847A1 (en) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
| US11254742B2 (en) | 2016-05-13 | 2022-02-22 | Bioatla, Inc. | Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
| CN107469089B (zh) * | 2016-06-07 | 2022-01-07 | 北京键凯科技股份有限公司 | 一种peg连接子及配基药物偶联物 |
| WO2017214182A1 (en) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
| CA3031559A1 (en) | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof |
| WO2018026890A1 (en) | 2016-08-03 | 2018-02-08 | Cymabay Therapeutics | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| CN110099682B (zh) | 2016-11-14 | 2023-03-31 | 杭州多禧生物科技有限公司 | 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用 |
| CA3036983A1 (en) | 2016-11-21 | 2018-05-24 | Cureab Gmbh | Anti-gp73 antibodies and immunoconjugates |
| EP3544983A2 (de) | 2016-11-23 | 2019-10-02 | Immunogen, Inc. | Selektive sulfonierung von benzodiazepinderivaten |
| US11236171B2 (en) | 2016-12-21 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
| CN110267685B (zh) | 2016-12-23 | 2023-06-20 | 伊缪诺金公司 | 靶向adam9的免疫缀合物及其使用方法 |
| US20180230218A1 (en) | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| PL3544636T3 (pl) | 2017-02-08 | 2021-12-06 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina-przeciwciało |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| RS63502B1 (sr) | 2017-04-18 | 2022-09-30 | Medimmune Ltd | Konjugati pirolobenzodiazepina |
| CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| US20180346488A1 (en) | 2017-04-20 | 2018-12-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
| WO2018213064A1 (en) | 2017-05-19 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting tnfer2 for cancer immunotherapy |
| US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
| WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
| CA3066953A1 (en) | 2017-06-30 | 2019-01-03 | Lentigen Technology, Inc. | Human monoclonal antibodies specific for cd33 and methods of their use |
| NZ761175A (en) | 2017-08-18 | 2024-07-26 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| KR20200061376A (ko) | 2017-09-29 | 2020-06-02 | 다이이찌 산쿄 가부시키가이샤 | 항체-피롤로벤조디아제핀 유도체 콘쥬게이트 |
| TW202413360A (zh) | 2017-12-28 | 2024-04-01 | 美商伊繆諾金公司 | 苯二氮平衍生物 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US11939377B2 (en) | 2018-07-12 | 2024-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Affinity matured CD22-specific monoclonal antibody and uses thereof |
| EP3833684A1 (de) | 2018-08-08 | 2021-06-16 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Gegen glypican-2 gerichtete, hochaffine monoklonale antikörper und verwendungen davon |
| TW202029980A (zh) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| EP3898693A4 (de) | 2018-12-21 | 2022-09-21 | Avidity Biosciences, Inc. | Anti-transferrin-rezeptor-antikörper und verwendungen davon |
| JP7542266B2 (ja) * | 2019-01-03 | 2024-08-30 | リガケム バイオサイエンシズ， インク． | 安定性が向上したピロロベンゾジアゼピン二量体化合物及びその用途 |
| CN113490510A (zh) | 2019-01-08 | 2021-10-08 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体 |
| AU2020212534A1 (en) | 2019-01-22 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| WO2020205564A1 (en) | 2019-03-29 | 2020-10-08 | Immunogen, Inc. | Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases |
| JP2022552875A (ja) | 2019-10-22 | 2022-12-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 多様な固形腫瘍を処置するためのｂ７ｈ３（ｃｄ２７６）を標的とする高親和性ナノボディ |
| CA3161573A1 (en) | 2019-12-12 | 2021-06-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-drug conjugates specific for cd276 and uses thereof |
| CA3172111A1 (en) | 2020-03-19 | 2021-09-23 | Barbora MALECOVA | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| MX2022011880A (es) | 2020-03-27 | 2022-10-20 | Avidity Biosciences Inc | Composiciones y metodos para tratar distrofia muscular. |
| US20230391852A1 (en) | 2020-10-26 | 2023-12-07 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
| WO2022232612A1 (en) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
| CN117500831A (zh) | 2021-06-09 | 2024-02-02 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体 |
| JP2024526764A (ja) | 2021-07-13 | 2024-07-19 | トゥルーバインディング，インコーポレイテッド | タンパク質凝集を防止する方法 |
| AU2022345098A1 (en) | 2021-09-16 | 2024-04-04 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| WO2023215737A1 (en) | 2022-05-03 | 2023-11-09 | Genentech, Inc. | Anti-ly6e antibodies, immunoconjugates, and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1516743A (fr) | 1966-04-01 | 1968-02-05 | Rhone Poulenc Sa | Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus |
| US4981979A (en) | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0563475B1 (de) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065 |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| AU757510C (en) | 1998-08-27 | 2003-09-11 | Medimmune Limited | Pyrrolobenzodiazepines |
| ATE349438T1 (de) | 1999-11-24 | 2007-01-15 | Immunogen Inc | Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| CA2504818C (en) | 2002-11-07 | 2013-04-23 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| DE60324607D1 (de) * | 2003-03-31 | 2008-12-18 | Council Scient Ind Res | Pyrrolo(2,1-c)(1,4)benzodiazepin-dimere als antitumormittel und verfahren dafür |
| WO2004091542A2 (en) | 2003-04-15 | 2004-10-28 | Covx Pharmaceuticals, Inc. | Nitrogen containing integrin targeting compounds |
| BRPI0412879A8 (pt) | 2003-07-21 | 2015-12-15 | Immunogen Inc | Conjugado citotóxico específico do antígeno ca6 e métodos de seu uso |
| GB0321295D0 (en) * | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| ATE516288T1 (de) * | 2003-10-22 | 2011-07-15 | Us Gov Health & Human Serv | Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren |
| GB0404578D0 (en) * | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0404577D0 (en) * | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| EP1723152B1 (de) | 2004-03-09 | 2015-02-11 | Spirogen Sàrl | Pyrrolobenzodiazepine |
| GB0410725D0 (en) * | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
| ATE527262T1 (de) * | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
| EP2044122B1 (de) * | 2006-07-18 | 2018-03-28 | Sanofi | Antagonisten-antikörper gegen epha-2 zur krebsbehandlung |
| EP1914242A1 (de) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Neue Antikörper gegen CD38 zur Behandlung von Krebs |
-
2007
- 2007-07-19 ES ES07290904T patent/ES2435779T3/es active Active
- 2007-07-19 PT PT72909047T patent/PT2019104E/pt unknown
- 2007-07-19 PL PL07290904T patent/PL2019104T3/pl unknown
- 2007-07-19 DK DK07290904.7T patent/DK2019104T3/da active
- 2007-07-19 SI SI200731354T patent/SI2019104T1/sl unknown
- 2007-07-19 EP EP07290904.7A patent/EP2019104B1/de active Active
-
2008
- 2008-07-16 PE PE2008001200A patent/PE20090889A1/es not_active Application Discontinuation
- 2008-07-16 PE PE2013000171A patent/PE20130590A1/es not_active Application Discontinuation
- 2008-07-17 JO JO2008323A patent/JO2744B1/en active
- 2008-07-17 AR ARP080103068A patent/AR067575A1/es not_active Application Discontinuation
- 2008-07-18 UA UAA201001752A patent/UA98153C2/uk unknown
- 2008-07-18 SI SI200830520T patent/SI2170890T1/sl unknown
- 2008-07-18 WO PCT/IB2008/002869 patent/WO2009016516A2/en active Application Filing
- 2008-07-18 TW TW097127553A patent/TWI500618B/zh not_active IP Right Cessation
- 2008-07-18 ES ES08826772T patent/ES2376026T3/es active Active
- 2008-07-18 KR KR1020107003573A patent/KR101627871B1/ko not_active IP Right Cessation
- 2008-07-18 CA CA2693551A patent/CA2693551C/en not_active Expired - Fee Related
- 2008-07-18 ME MEP-2010-4A patent/ME00969B/me unknown
- 2008-07-18 BR BRPI0814267 patent/BRPI0814267A2/pt not_active Application Discontinuation
- 2008-07-18 CL CL2008002139A patent/CL2008002139A1/es unknown
- 2008-07-18 PT PT08826772T patent/PT2170890E/pt unknown
- 2008-07-18 DK DK08826772.9T patent/DK2170890T3/da active
- 2008-07-18 PL PL08826772T patent/PL2170890T3/pl unknown
- 2008-07-18 EP EP08826772A patent/EP2170890B1/de active Active
- 2008-07-18 EA EA201070163A patent/EA019938B1/ru not_active IP Right Cessation
- 2008-07-18 JP JP2010516613A patent/JP5551070B2/ja not_active Expired - Fee Related
- 2008-07-18 MY MYPI20100202 patent/MY151245A/en unknown
- 2008-07-18 AT AT08826772T patent/ATE530553T1/de active
- 2008-07-18 PA PA20088790201A patent/PA8790201A1/es unknown
- 2008-07-18 RS RS20120026A patent/RS52245B/en unknown
- 2008-07-18 NZ NZ582679A patent/NZ582679A/en not_active IP Right Cessation
- 2008-07-18 AU AU2008281439A patent/AU2008281439B2/en not_active Ceased
- 2008-07-18 CN CN200880103551.3A patent/CN101784550B/zh not_active Expired - Fee Related
-
2010
- 2010-01-04 TN TNP2010000002A patent/TN2010000002A1/fr unknown
- 2010-01-11 NI NI201000005A patent/NI201000005A/es unknown
- 2010-01-11 DO DO2010000014A patent/DOP2010000014A/es unknown
- 2010-01-12 GT GT201000008A patent/GT201000008A/es unknown
- 2010-01-14 IL IL203318A patent/IL203318A/en not_active IP Right Cessation
- 2010-01-14 EC EC2010009875A patent/ECSP109875A/es unknown
- 2010-01-18 CR CR11225A patent/CR11225A/es unknown
- 2010-01-19 ZA ZA2010/00389A patent/ZA201000389B/en unknown
- 2010-01-19 CO CO10004826A patent/CO6290692A2/es active IP Right Grant
- 2010-01-19 US US12/689,797 patent/US8404678B2/en active Active
- 2010-02-17 MA MA32630A patent/MA31617B1/fr unknown
- 2010-11-24 HK HK10110900A patent/HK1144289A1/xx not_active IP Right Cessation
-
2012
- 2012-01-23 HR HR20120067T patent/HRP20120067T1/hr unknown
- 2012-01-26 CY CY20121100093T patent/CY1112278T1/el unknown
-
2013
- 2013-12-03 CY CY20131101083T patent/CY1114922T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120067T1 (hr) | Citotoksična sredstva koja sadrže nove derivate tomamicina i njihova upotreba u terapiji | |
| HRP20140307T1 (hr) | Citotoksiäśna sredstva koja sadrže nove derivate tomamicina i njihova upotreba u terapiji | |
| WO2023078021A1 (en) | Bcma monoclonal antibody and the antibody-drug conjugate | |
| CA3107417C (en) | Effective method for manufacturing antibody-drug conjugate | |
| JP6681346B2 (ja) | オーリスタチン誘導体およびその抱合体 | |
| KR102490719B1 (ko) | 항cd70 항체 약물 컨쥬게이트 | |
| TWI819474B (zh) | 細胞毒性苯并二氮呯衍生物 | |
| JP2023090748A (ja) | 二官能性キレートの薬物動態増強及びその使用 | |
| JP7191938B2 (ja) | Ｉｇｆ－１ｒモノクローナル抗体及びその使用 | |
| JP2021506883A (ja) | ピロロベンゾジアゼピン抗体結合体 | |
| JP2021063098A (ja) | 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体 | |
| US20200138970A1 (en) | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with antib7h3-antibodies | |
| US10280229B2 (en) | Linkers and their application towards ADC | |
| US20180185510A1 (en) | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies | |
| HRP20211626T1 (hr) | Spojevi cikličkog peptidtirozina tirozina vezani na protutijelo kao modulatori receptora za neuropeptid y | |
| CN105682656A (zh) | 调节法尼醇x受体的组合物和方法 | |
| JP7169296B2 (ja) | 結合剤 | |
| CA3154302A1 (en) | Stable, concentrated radiopharmaceutical composition | |
| JPWO2019203191A1 (ja) | 修飾抗体、および、放射性金属標識抗体 | |
| WO2022014698A1 (ja) | 抗体－薬物コンジュゲートの製造方法 | |
| JP2020508355A (ja) | 腫瘍成長を阻害し且つ腫瘍に対する免疫反応を増強するための方法及び組成物 | |
| US9453046B2 (en) | Activated carbon filtration for purification of benzodiazepine ADCs | |
| CN118765273A (zh) | 靶向EGFR-cMET的化合物及其用途 | |
| CN118317796A (zh) | EGFRvIII靶向化合物及其用途 | |
| CN117338949A (zh) | 一种带有高稳定性亲水连接单元的奥瑞他汀类药物及其偶联物 |